Alixorexton, a selective orexin 2 receptor agonist, improves wakefulness in narcolepsy type 1
In a phase 2 randomized controlled trial, alixorexton (4, 6, or 8 mg once daily) significantly increased mean sleep latency on the Maintenance of Wakefulness Test compared to placebo at 6 weeks. Placebo-corrected improvements were 22.2, 24.1, and 26.0 minutes for the 4, 6, and 8 mg doses, respectively. The drug was generally well tolerated, with adverse events consistent with on-target OX2R agonism.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Alixorexton, a selective orexin 2 receptor agonist, improves wakefulness in narcolepsy type 1 The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 44/100 (low).
The Claim
Alixorexton, a selective orexin 2 receptor agonist, improves wakefulness in narcolepsy type 1
This conclusion is most relevant to: Adults (aged 18-70 years) with narcolepsy type 1.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial. (The Lancet. Neurology, 2026) —
How It Works
The proposed biological pathway:
- ▸Alixorexton binds to and activates orexin 2 receptors (OX2R) in the brain
- ▸OX2R activation promotes wakefulness and suppresses rapid eye movement sleep
- ▸This leads to increased alertness and reduced cataplexy in narcolepsy type 1
- ▸Result: Significant improvement in mean sleep latency on MWT
Who Might Benefit
Evidence fit by population:
- ▸Adults (aged 18-70 years) with narcolepsy type 1
Recommended Dose
4 mg, 6 mg, or 8 mg once daily (all doses effective; no clear dose-response)
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Phase 2 trial with relatively small sample size (n=92)
- ▸Short duration (6 weeks) and no long-term safety data
- ▸Open-label extension may introduce bias
- ▸No comparison with existing treatments (e.g., modafinil, pitolisant)
Frequently Asked Questions
What is alixorexton?▼
Alixorexton is an oral selective orexin 2 receptor agonist being investigated for narcolepsy type 1.
How effective is alixorexton for narcolepsy?▼
In this phase 2 trial, alixorexton improved mean sleep latency by about 22-26 minutes compared to placebo at 6 weeks, which is clinically meaningful.
What are the common side effects of alixorexton?▼
Common side effects (in ≥5% of patients) included frequent urination (pollakiuria), insomnia, increased salivation, urgency to urinate, blurred vision, and excessive sweating.
Is alixorexton approved for narcolepsy?▼
No, this is a phase 2 trial. Further phase 3 evaluation is needed before regulatory approval.
References
- 1.Plazzi G, Grunstein RR, Mignot E, Lammers GJ, Plante DT, Buntinx E, Del Río Villegas R, Chen H, Lovett A, Doane MJ, Hopkinson C, Rege B, Himes J, Dauvilliers Y. “Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial..” The Lancet. Neurology, 2026. PMID: 42636845 DOI: 10.1016/S1474-4422(26)00278-4